Dietary fatty acids and the aging brain.

Aging contributes to physiological decline and vulnerability to disease. In the brain, even with minimal neuronal loss, aging increases oxidative damage, inflammation, demyelination, impaired processing, and metabolic deficits, particularly during pathological brain aging. In this review, the possible role of docosahexaenoic acid (DHA) in the prevention of age-related disruption of brain function is discussed. High-fat diabetogenic diets, cholesterol, and the omega-6 fatty acid arachidonate and its prostaglandin metabolites have all been implicated in promoting the pathogenesis of Alzheimer's disease. Evidence presented here shows DHA acts to oppose this, exerting a plethora of pleiotropic activities to protect against the pathogenesis of Alzheimer's disease.

[1]  Michael Weiner,et al.  Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. , 2010, JAMA.

[2]  A. Blackwell,et al.  Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline , 2010, Alzheimer's & Dementia.

[3]  Marcus Richards,et al.  Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. , 2010, The American journal of clinical nutrition.

[4]  P. Scheltens,et al.  Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial , 2010, Alzheimer's & Dementia.

[5]  Z. Wszolek,et al.  VASCULAR RISK FACTORS AND DEMENTIA: HOW TO MOVE FORWARD? , 2009, Neurology.

[6]  G. Cole,et al.  Omega-3 fatty acids and dementia. , 2009, Prostaglandins, leukotrienes, and essential fatty acids.

[7]  S. Rapoport,et al.  Can the rat liver maintain normal brain DHA metabolism in the absence of dietary DHA? , 2009, Prostaglandins, leukotrienes, and essential fatty acids.

[8]  H. Vinters,et al.  β-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin , 2009, The Journal of Neuroscience.

[9]  Libin Cui,et al.  Improved spatial learning performance of fat-1 mice is associated with enhanced neurogenesis and neuritogenesis by docosahexaenoic acid , 2009, Proceedings of the National Academy of Sciences.

[10]  O. Shido,et al.  Docosahexaenoic acid promotes neuronal differentiation by regulating basic helix–loop–helix transcription factors and cell cycle in neural stem cells , 2009, Neuroscience.

[11]  Suzanne Craft,et al.  The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. , 2009, Archives of neurology.

[12]  R. Mayeux,et al.  Mediterranean diet and mild cognitive impairment. , 2009, Archives of neurology.

[13]  R. Wurtman,et al.  Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  L. Mucke,et al.  Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease , 2008, Nature Neuroscience.

[15]  S. Faraone,et al.  Diabetes and overweight associate with non‐APOE4 genotype in an alzheimer's disease population , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[16]  Osman A. B. S. M. Gani,et al.  Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha. , 2008, Journal of molecular graphics & modelling.

[17]  F. Gomez-Pinilla,et al.  Docosahexaenoic acid dietary supplementation enhances the effects of exercise on synaptic plasticity and cognition , 2008, Neuroscience.

[18]  Shih-Yi Huang,et al.  The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[19]  Takashi Morihara,et al.  Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer's Disease , 2008, Journal of Pharmacology and Experimental Therapeutics.

[20]  G. Cole,et al.  p21-activated Kinase-aberrant Activation and Translocation in Alzheimer Disease Pathogenesis* , 2008, Journal of Biological Chemistry.

[21]  P. Rzehak,et al.  Evidence for an association between genetic variants of the fatty acid desaturase 1 fatty acid desaturase 2 (FADS1 FADS2) gene cluster and the fatty acid composition of erythrocyte membranes , 2008, British Journal of Nutrition.

[22]  S. Wassall,et al.  Docosahexaenoic acid domains: the ultimate non-raft membrane domain. , 2008, Chemistry and physics of lipids.

[23]  J. O’Keefe,et al.  Omega-3 fatty acids for cardioprotection. , 2008, Mayo Clinic proceedings.

[24]  B. Teter,et al.  Omega-3 Fatty Acid Docosahexaenoic Acid Increases SorLA/LR11, a Sorting Protein with Reduced Expression in Sporadic Alzheimer's Disease (AD): Relevance to AD Prevention , 2007, The Journal of Neuroscience.

[25]  F. Calderon,et al.  Role of RXR in neurite outgrowth induced by docosahexaenoic acid. , 2007, Prostaglandins, leukotrienes, and essential fatty acids.

[26]  F. Pifferi,et al.  n-3 Fatty acids modulate brain glucose transport in endothelial cells of the blood-brain barrier. , 2007, Prostaglandins, leukotrienes, and essential fatty acids.

[27]  F. Schmitt,et al.  Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment , 2007, Neurology.

[28]  Frank M LaFerla,et al.  Dietary Docosahexaenoic Acid and Docosapentaenoic Acid Ameliorate Amyloid-β and Tau Pathology via a Mechanism Involving Presenilin 1 Levels , 2007, The Journal of Neuroscience.

[29]  S. Innis,et al.  Dietary (n-3) fatty acids and brain development. , 2007, The Journal of nutrition.

[30]  J. Silverman,et al.  Cardiovascular risk factors for Alzheimer's disease. , 2007, The American journal of geriatric cardiology.

[31]  Jim Mintz,et al.  Brain ferritin iron may influence age- and gender-related risks of neurodegeneration , 2007, Neurobiology of Aging.

[32]  G. Cole,et al.  The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer’s Disease , 2007, Experimental Gerontology.

[33]  Rhoda Au,et al.  Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. , 2006, Archives of neurology.

[34]  Dariush Mozaffarian,et al.  Fish intake, contaminants, and human health: evaluating the risks and the benefits. , 2006, JAMA.

[35]  Michio Hashimoto,et al.  DOCOSAHEXAENOIC ACID‐INDUCED PROTECTIVE EFFECT AGAINST IMPAIRED LEARNING IN AMYLOID β‐INFUSED RATS IS ASSOCIATED WITH INCREASED SYNAPTOSOMAL MEMBRANE FLUIDITY , 2006, Clinical and experimental pharmacology & physiology.

[36]  Noriyuki Matsukawa,et al.  Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction , 2006, Neuroscience Research.

[37]  Lars-Olof Wahlund,et al.  Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. , 2006, Archives of neurology.

[38]  H. Tanila,et al.  Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice , 2006, Neurobiology of Disease.

[39]  G. Cole,et al.  Docosahexaenoic Acid Protects from Amyloid and Dendritic Pathology in an Alzheimer's Disease Mouse Model , 2006, Nutrition and health.

[40]  A D Roses,et al.  Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease , 2006, The Pharmacogenomics Journal.

[41]  J. Wuu,et al.  Differential Expression of Synaptic Proteins in the Frontal and Temporal Cortex of Elderly Subjects With Mild Cognitive Impairment , 2006, Journal of neuropathology and experimental neurology.

[42]  Yaakov Stern,et al.  Mediterranean diet and risk for Alzheimer's disease , 2006, Annals of neurology.

[43]  R. Mahley,et al.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[44]  R. Koch,et al.  Omega-3 fatty acids improve the diagnosis-related clinical outcome* , 2006, Critical care medicine.

[45]  B. Teter,et al.  Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease , 2006, Nature Neuroscience.

[46]  Charles N Serhan,et al.  A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. , 2005, The Journal of clinical investigation.

[47]  Zhiming Wen,et al.  Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Takashi Morihara,et al.  Dietary n‐3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease , 2005, The European journal of neuroscience.

[49]  B. Teter,et al.  Insulin-Degrading Enzyme as a Downstream Target of Insulin Receptor Signaling Cascade: Implications for Alzheimer's Disease Intervention , 2004, The Journal of Neuroscience.

[50]  C. Finch,et al.  Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers , 2004, The Journal of Neuroscience.

[51]  Takashi Morihara,et al.  Docosahexaenoic Acid Protects from Dendritic Pathology in an Alzheimer's Disease Mouse Model , 2004, Neuron.

[52]  T. Montine,et al.  Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. , 2004, Chemistry and physics of lipids.

[53]  G. Barceló-Coblijn,et al.  Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[54]  L. Launer,et al.  Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. , 2002, Diabetes.

[55]  Ger J. A. Ramakers,et al.  Rho proteins, mental retardation and the cellular basis of cognition , 2002, Trends in Neurosciences.

[56]  D. C. Mitchell,et al.  The role of docosahexaenoic acid containing phospholipids in modulating G protein-coupled signaling pathways , 2001, Journal of Molecular Neuroscience.

[57]  E. Masliah,et al.  Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease , 2001, Neurology.

[58]  T. Perlmann,et al.  Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. , 2000, Science.

[59]  R. Terry.  Cell death or synaptic loss in Alzheimer disease. , 2000, Journal of neuropathology and experimental neurology.

[60]  Richard Weindruch,et al.  Gene-expression profile of the ageing brain in mice , 2000, Nature Genetics.

[61]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[62]  S. Nishiyama,et al.  Docosahexaenoic acid (DHA) improves the age-related impairment of the coupling mechanism between neuronal activation and functional cerebral blood flow response: a PET study in conscious monkeys , 2000, Brain Research.

[63]  Y. Christen,et al.  Oxidative Insults Are Associated with Apolipoprotein E Genotype in Alzheimer's Disease Brain , 2000, Neurobiology of Disease.

[64]  M. Hossain,et al.  Antioxidative Effects of Docosahexaenoic Acid in the Cerebrum Versus Cerebellum and Brainstem of Aged Hypercholesterolemic Rats , 1999, Journal of neurochemistry.

[65]  B. Halliwell,et al.  F4 ‐ Isoprostanes as Specific Marker of Docosahexaenoic Acid Peroxidation in Alzheimer's Disease , 1999, Journal of neurochemistry.

[66]  A. Ott.  Risk of dementia: The Rotterdam Study , 1997 .

[67]  T. Montine,et al.  4‐Hydroxy‐2‐Nonenal Pyrrole Adducts in Human Neurodegenerative Disease , 1997, Journal of neuropathology and experimental neurology.

[68]  J. Lorber,et al.  RECIPROCAL NEUROLOGICAL DEVELOPMENTS OF TWINS DISCORDANT FOR HYDROCEPHALUS , 1992, Developmental medicine and child neurology.

[69]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[70]  Paul D. Coleman,et al.  Neuron numbers and dendritic extent in normal aging and Alzheimer's disease , 1987, Neurobiology of Aging.

[71]  J. Lorber,et al.  Brain and ventricular volume in hydrocephalus. , 1984, Zeitschrift fur Kinderchirurgie : organ der Deutschen, der Schweizerischen und der Osterreichischen Gesellschaft fur Kinderchirurgie = Surgery in infancy and childhood.

[72]  J. Lorber.  Is your brain really necessary? , 1981, Nursing mirror.

[73]  R. Castellani,et al.  Alzheimer disease. , 2010, Disease-a-month : DM.

[74]  L. Kuller,et al.  Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. , 2008, Archives of neurology.

[75]  Gerald Rimbach,et al.  Impact of apoE genotype on oxidative stress, inflammation and disease risk. , 2008, Molecular nutrition & food research.

[76]  S. Rapoport,et al.  n-3 Polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism , 2007, Molecular Psychiatry.

[77]  C. Finch,et al.  Synaptic targeting by Alzheimer's-related amyloid beta oligomers. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.